Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease due to a lytic infection of oligodendrocytes caused by John Cunningham polyoma virus (JCV) infection. Idiopathic CD4+ T-cell lymphocytopenia (ICL) is a very rare cause of PML.
METHODS: We present an individual with PML secondary to ICL treated with 3 doses of pembrolizumab, a Programmed-Death-1 Immune Checkpoint Inhibitor following with complete resolution of symptoms and conduct a review of the literature.
CONCLUSION: This report illustrates the objective clinical and radiological improvement in a patient with PML due to ICL and suggests further study of immune checkpoint inhibitors as potential treatment for patients with PML.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:385 |
|---|---|
| Enthalten in: |
Journal of neuroimmunology - 385(2023) vom: 15. Dez., Seite 578248 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varmpompiti, Kyriakoula [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 18.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jneuroim.2023.578248 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364868546 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364868546 | ||
| 003 | DE-627 | ||
| 005 | 20240118231955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jneuroim.2023.578248 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1263.xml |
| 035 | |a (DE-627)NLM364868546 | ||
| 035 | |a (NLM)37995595 | ||
| 035 | |a (PII)S0165-5728(23)00234-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varmpompiti, Kyriakoula |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Progressive multifocal leukoencephalopathy secondary to idiopathic CD4 lymphocytopenia treated with pembrolizumab |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating disease due to a lytic infection of oligodendrocytes caused by John Cunningham polyoma virus (JCV) infection. Idiopathic CD4+ T-cell lymphocytopenia (ICL) is a very rare cause of PML | ||
| 520 | |a METHODS: We present an individual with PML secondary to ICL treated with 3 doses of pembrolizumab, a Programmed-Death-1 Immune Checkpoint Inhibitor following with complete resolution of symptoms and conduct a review of the literature | ||
| 520 | |a CONCLUSION: This report illustrates the objective clinical and radiological improvement in a patient with PML due to ICL and suggests further study of immune checkpoint inhibitors as potential treatment for patients with PML | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Idiopathic lymphocytopenia | |
| 650 | 4 | |a John Cunningham Virus | |
| 650 | 4 | |a Neuroinflammation | |
| 650 | 4 | |a PD-1 Checkpoint Inhibitor | |
| 650 | 4 | |a Pembrolizumab | |
| 650 | 4 | |a Progressive multifocal leukoencephalopathy | |
| 650 | 7 | |a pembrolizumab |2 NLM | |
| 650 | 7 | |a DPT0O3T46P |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 700 | 1 | |a Westwood, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Ben-Joseph, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Sibtain, Naomi |e verfasserin |4 aut | |
| 700 | 1 | |a Ibrahim, Mohammad A A |e verfasserin |4 aut | |
| 700 | 1 | |a Stanton, Biba |e verfasserin |4 aut | |
| 700 | 1 | |a Zuckerman, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Hadden, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Ritter, Laura Mantoan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuroimmunology |d 1985 |g 385(2023) vom: 15. Dez., Seite 578248 |w (DE-627)NLM012614181 |x 1872-8421 |7 nnns |
| 773 | 1 | 8 | |g volume:385 |g year:2023 |g day:15 |g month:12 |g pages:578248 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jneuroim.2023.578248 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 385 |j 2023 |b 15 |c 12 |h 578248 | ||